Overdose Prevention Strategy

General Research. Featured Activity Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis Lead Agency: FDA Modeling the evolution of the US opioid crisis for national policy development To improve access to and quality of substance use disorder treatment for Medicaid beneficiaries, Section 1115 Substance Use Disorder (SUD) Demonstrations provide state programs with funding to develop innovative solutions to address local concerns about health services provided and to phase in a range of strategies to address those concerns. Learn about Modeling the evolution of the US opioid crisis Lead Agency: FDA Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis Lead Agency: FDA Testing for Fentanyl — Urgent Need for Practice-Relevant and Public Health Research Lead Agency: NIH Partner Agency: FDA Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest Lead Agency: FDA Effect of Paroxetine or Quetiapine Combined with Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial Lead Agency: FDA Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest Lead Agency: FDA Understanding syringeability and injectability of high molecular weight PEO solution through time-dependent force-distance profiles Lead Agency: FDA Understanding syringeability and injectability of high molecular weight PEO solution through time-dependent force-distance profiles Lead Agency: FDA Amphetamines modulate fentanyl-depressed respiration in a bidirectional manner Lead Agency: FDA Asymmetrical Flow Field Flow Fractionation for Molar Mass Characterization of Polyethylene Oxide in Abuse-Deterrent Formulations Lead Agency: FDA Stability of Abuse-deterrent properties of PEO-based Abuse-deterrent formulation Lead Agency: FDA Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance Lead Agency: FDA State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies Lead Agency: FDA Determination of structural factors affecting binding to mu, kappa and delta opioid receptors Lead Agency: FDA Relative Effectiveness of Social Media, Dating Apps, and Information Search Sites in Promoting HIV Self-testing: Observational Cohort Study Lead Agency: NIH Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to End Addiction Long-term SM) communities study Lead Agency: NIH Partner Agency: SAMHSA The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses Lead Agency: NIH Rural communities face more than an opioid crisis: Reimagining funding assistance to address polysubstance use, associated health problems, and limited rural service capacity Lead Agency: HRSA Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018 Lead Agency: CDC Trends in State-Level Pharmacy-Based Naloxone Dispensing Rates, 2012-2019 Lead Agency: CDC Concurrent Naloxone dispensing among individuals with high-risk opioid prescriptions, United States, 2015-2019 Lead Agency: CDC Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System, 2019 Lead Agency: CDC Trends in Pharmacy-Based Dispensing of Buprenorphine, Extended-Release Naltrexone, and Naloxone During the COVID-19 Pandemic by Age and Sex – United States, March 2019 – December 2020 Lead Agency: CDC